Detalhe da pesquisa
1.
Cost-effectiveness of nivolumab and ipilimumab versus pembrolizumab and axitinib in advanced renal cell carcinoma with intermediate or poor prognostic risk: a Brazilian private healthcare system perspective.
J Med Econ
; 26(1): 1108-1121, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-37632452
2.
A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415).
Eur J Cancer
; 158: 63-71, 2021 Oct 13.
Artigo
Inglês
| MEDLINE | ID: mdl-34655838
3.
Prognostic Value of Systemic Inflammatory Biomarkers in Patients with Metastatic Renal Cell Carcinoma.
Pathol Oncol Res
; 26(4): 2489-2497, 2020 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-32583330
4.
Analysis of Efficacy and Toxicity Profile of First-Line Sunitinib or Pazopanib in Metastatic Clear Cell Renal Cell Carcinoma in the Brazilian Population.
J Glob Oncol
; 4: 1-10, 2018 08.
Artigo
Inglês
| MEDLINE | ID: mdl-30199304